Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Marvelbiome Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 examiners and 3 art units, so each pending matter has a distinct examination assignment in the available record.
BREEN, KIMBERLY CATHERINE is the busiest examiner, with 1 pending matter. Counsel should manage the matters individually and tailor claim and response strategy to each examiner and art unit.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BREEN, KIMBERLY CATHERINE | 1 | 23.8% | +56.3% |
| EDWARDS, JESSICA FAYE | 1 | 38.3% | +47.2% |
| REGLAS, GEORGIANA C | 1 | 39.2% | +33.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19112201 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | BREEN, KIMBERLY CATHERINE | 75d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18073511 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING VAGUS NERVE ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | REGLAS, GEORGIANA C | 38d overdue |
| 18244685 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING EYE DISORDERS | EDWARDS, JESSICA FAYE | 5d overdue |
| 19112201 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | BREEN, KIMBERLY CATHERINE | 75d |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1657 | 1 |
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19112201 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | BREEN, KIMBERLY CATHERINE | 1653 | §101§102§103§112Other | Non-Final OA | 75d | Pending | Mar 14, 2025 |
| 18244685 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING EYE DISORDERS | EDWARDS, JESSICA FAYE | 1657 | §112DP | Final Rejection | 5d overdue | Pending | Sep 11, 2023 |
| 18073511 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING VAGUS NERVE ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | REGLAS, GEORGIANA C | 1651 | §112 | Final Rejection | 38d overdue | Pending | Dec 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMarvelbiome Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Kimberly Catherine Breen has the most, with 1 of Marvelbiome Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
